In the largest and most conclusive study of its kind, researchers have analysed blood samples to create a novel and non-invasive way of helping to diagnose Alzheimer’s disease and distinguish between different types of neurodegenerative disorders.
Following this breakthrough discovery, Alzheimer’s sufferers may now have an additional test to improve the accuracy of diagnosis in order to better tailor appropriate treatment.
The research also offers a valuable opportunity to monitor the progression of the disease.
The international study in the Proceedings of the National Academy of Sciences USA used sensor-based technology with a diamond core to analyse approximately 550 blood samples.
By passing light through the diamond and observing its interactions with the blood plasma, researchers were able to identify specific chemical bonds within the blood. This biochemical data was used to compare blood samples from cases of Alzheimer’s disease and other neurodegenerative diseases with those from healthy controls.
The ground-breaking scientific investigation was carried out by researchers at Lancaster University, the University of Central Lancashire (UCLan), the University of Manchester and the Federal University of Rio Grande do Norte, Brazil.
Professor David Allsop from Lancaster University has been collaborating for many years withProfessor David Mann from the University of Manchester in searching for diagnostic markers for neurodegenerative disease in blood plasma.
They provided all of the plasma samples for the study, along with supporting clinical and genetic information, and expertise in Alzheimer’s and other neurodegenerative conditions.
Professor Allsop said: “A particularly exciting aspect of the study was the ability to distinguish accurately between Alzheimer’s disease and Lewy body dementia, which are conditions that both result in dementia and can be difficult to separate from each other based on clinical information and symptoms. By reduction of misdiagnosed cases and administration of appropriate treatment, many people could benefit from this type of blood test in the future.”
Alzheimer’s diagnosis currently involves careful medical evaluation including clinical history, memory testing and brain scans, yet the only conclusive diagnosis is determined by post-mortem examination. This new blood test offers a non-invasive, more accurate and relatively cost-effective method of diagnosis, which will ensure the correct management of the condition.
Professor Francis Martin, principal investigator of the study and Biosciences theme lead at UCLan, said: “We have an aging population, meaning that the incidence and prevalence of Alzheimer’s is increasing, as is the need for accurate diagnosis. The ability to identify different neurodegenerative diseases through the analysis of blood offers a faster and accurate way of establishing the most effective treatment plan as well as disease monitoring.”
This new approach could also offer potential for carrying out tests to identify and monitor early signs of mild cognitive impairment, meaning that the onset of Alzheimer’s and other types of neurodegenerative diseases could be detected early and intervention measures could be put in place earlier to slow the progress of these diseases.
Professor Martin added: “For those suffering with Alzheimer’s disease, the damage is already well advanced once conventionally diagnosed, but this new method offers a potentially effective early screening tool when patients are only demonstrating signs of mild cognitive impairment. This is a potentially significant breakthrough for the prevention of different debilitating and chronic neurological diseases.”
The Latest on: Alzheimer’s
- Dr. Charlie Farrell – Alzheimer’s Disease Awareness Swim from Alcatrazon November 15, 2019 at 10:55 am
The numbers are staggering… right now, about a quarter million people are living with Alzheimer's disease in Ohio. That's the most common type of dementia. And more than 600-thousand family and ...
- Dr. Jeff Reech – Understanding Alzheimer’s and Being a Caregiveron November 15, 2019 at 10:53 am
Leon was joined by Dr. Jeff Reech, the Clinical Consultation manager at the Cleveland Chapter of the Alzheimer's Association. What are some of the most pressing concerns family caregivers have when ...
- Grant to assist in funding Memory Garden for those with dementia, Alzheimer’s at Will Rogers Gardenson November 15, 2019 at 9:28 am
OKLAHOMA CITY (KFOR) – Friends of Will Rogers Gardens Foundation recently received a grant that will be used to fund a Memory Garden project designed for those with dementia or Alzheimer’s. Earlier ...
- Many patients with iNPH develop Alzheimer's disease, tooon November 15, 2019 at 7:58 am
Up to one in five patients treated for idiopathic normal pressure hydrocephalus, iNPH, also develop Alzheimer's disease, according to a new study from the University of Eastern Finland and Kuopio ...
- 5 stories to read for Alzheimer’s Awareness Monthon November 15, 2019 at 7:35 am
In 1983, President Ronald Reagan designated November as Alzheimer’s Awareness Month, and it has been considered as such in the United States each year since. According to data from the CDC, as many as ...
- 3 Steps for Leonard Skinner: Coach’s team walks for Alzheimer’s cureon November 14, 2019 at 1:29 pm
Lynyrd Sknyrd. Yet nothing could prevent his Alzheimer’s disease as it worsened, and Leonard Skinner knew what was happening to him when he felt his mind and his memory slipping away. “He used to call ...
- Students Demand Presidential Candidates ‘Make Alzheimer’s The Nation’s Top Health Priority’on November 14, 2019 at 1:01 pm
Why would a 25-year-old medical student attend a summit on Alzheimer’s disease in the nation’s capital? And why is he thinking about dementia at all? Nihal Satyadev said he wants to change everyone’s ...
- A Quixote with Alzheimer’s, trying to make sense of a new landscapeon November 14, 2019 at 10:55 am
And instead of a wannabe knight who’s been seemingly driven mad, the central character in “Quixote Nuevo” is a retired college professor, Jose “Joe” Quijano, a Cervantes scholar now saddled with ...
- The most promising breakthrough in Alzheimer’s treatment is not a drugon November 14, 2019 at 8:23 am
Alzheimer’s, one of the direst health threats in the US, is not showing signs of slowing down. The neurodegenerative disease that leads to brain cell degeneration and a decline in cognitive functions ...
- Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship withon November 14, 2019 at 8:05 am
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET * Topline results expected before the end of Q1/2020 REHOVOT, Israel ...
via Google News and Bing News